Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tanruprubart · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Tanruprubart | EXPERIMENTAL | Participants will receive a single 30 mg/kg intravenous (IV) infusion of tanruprubart on Day 1. |
| Name | Type | Description |
|---|---|---|
| Tanruprubart | DRUG | Solution for IV infusion. |
Key Inclusion Criteria: * Diagnosis of GBS according to the National Institute of Neurological Disorders and Stroke Diagnostic Criteria for GBS. * Onset of GBS-related weakness ≤10 days before start of infusion on Day 1 * GBS-disability score (DS) score of 3, 4, or 5 at screening and before start o...
Tanruprubart is an investigational small molecule being developed for the treatment of Guillain-Barre Syndrome, a rare neurological disorder. It is currently in Phase 3 clinical development and has not been approved by the FDA. The drug has received Fast Track and Orphan Drug designations from the FDA.
Tanruprubart is being developed by Annexon, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ANNX. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Guillain-Barre Syndrome.
Tanruprubart is currently in Phase 3 clinical development. It is being studied in an open-label, uncontrolled clinical trial for Guillain-Barre Syndrome. The drug has not yet been approved by the FDA and remains investigational. It has received Fast Track and Orphan Drug designations.
Tanruprubart is being evaluated in a Phase 3 clinical trial with the identifier NCT07020819, known as the FORWARD Study. This open-label, uncontrolled trial is recruiting 30 participants with Guillain-Barre Syndrome at sites in the United States and Denmark. The trial is currently recruiting participants aged 12 years and older.
Yes, Tanruprubart is also commonly known as ANX005. The clinical trial NCT07020819 explicitly refers to the drug as Tanruprubart (Also Commonly Known as ANX005). This alternative name is used in the FORWARD Study for participants with Guillain-Barre Syndrome.
The FORWARD Study is a Phase 3, open-label, uncontrolled clinical trial evaluating Tanruprubart in participants with Guillain-Barre Syndrome. The trial, identified as NCT07020819, is recruiting 30 participants across the United States and Denmark. It is not randomized or double-blinded and does not use a control group.